Related references
Note: Only part of the references are listed.Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
Antonius A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
A. A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
Ming Zhao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A Lego system for conditional inference
Torsten Hothorn et al.
AMERICAN STATISTICIAN (2006)
The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A historical perspective
Mark J. Ratain et al.
CLINICAL CANCER RESEARCH (2006)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Raf: A strategic target for therapeutic development against cancer
M Beeram et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
JW Clark et al.
CLINICAL CANCER RESEARCH (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High-throughout determination of the free fraction of drugs strongly bound to plasma proteins
J Schuhmacher et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
AP Venook et al.
ANNALS OF ONCOLOGY (2003)
BAY 43-9006: Early clinical data in patients with advanced solid malignancies
SJ Hotte et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565
AP Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
